[go: up one dir, main page]

MX2020011668A - Antagonistas duales de receptores de neurocinina-1 (nk-1)/neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales. - Google Patents

Antagonistas duales de receptores de neurocinina-1 (nk-1)/neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales.

Info

Publication number
MX2020011668A
MX2020011668A MX2020011668A MX2020011668A MX2020011668A MX 2020011668 A MX2020011668 A MX 2020011668A MX 2020011668 A MX2020011668 A MX 2020011668A MX 2020011668 A MX2020011668 A MX 2020011668A MX 2020011668 A MX2020011668 A MX 2020011668A
Authority
MX
Mexico
Prior art keywords
sex
dual
treatment
receptor antagonists
hormone
Prior art date
Application number
MX2020011668A
Other languages
English (en)
Inventor
Mike Trower
Original Assignee
Kandy Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56008636&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020011668(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kandy Therapeutics Ltd filed Critical Kandy Therapeutics Ltd
Publication of MX2020011668A publication Critical patent/MX2020011668A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Multicomponent Fibers (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Esta invención se refiere al nuevo uso de antagonistas duales de receptores NK-1/NK-3 o una sal farmacéuticamente aceptable de éstos en el tratamiento de enfermedades dependientes de hormonas sexuales.
MX2020011668A 2015-05-18 2017-10-03 Antagonistas duales de receptores de neurocinina-1 (nk-1)/neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales. MX2020011668A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562162870P 2015-05-18 2015-05-18

Publications (1)

Publication Number Publication Date
MX2020011668A true MX2020011668A (es) 2021-01-15

Family

ID=56008636

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017012720A MX377052B (es) 2015-05-18 2016-05-16 Antagonistas duales de receptores de neurocinina-1 (nk-1) / neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales.
MX2020011668A MX2020011668A (es) 2015-05-18 2017-10-03 Antagonistas duales de receptores de neurocinina-1 (nk-1)/neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017012720A MX377052B (es) 2015-05-18 2016-05-16 Antagonistas duales de receptores de neurocinina-1 (nk-1) / neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales.

Country Status (22)

Country Link
US (4) US10195205B2 (es)
EP (2) EP3574907B1 (es)
JP (1) JP6902682B2 (es)
KR (1) KR102704783B1 (es)
CN (4) CN114306347A (es)
AU (2) AU2016264034B2 (es)
BR (1) BR112017024852B1 (es)
CA (1) CA2984591A1 (es)
CY (1) CY1122180T1 (es)
DK (1) DK3297631T3 (es)
ES (1) ES2753539T3 (es)
HR (1) HRP20192132T1 (es)
HU (1) HUE047732T2 (es)
LT (1) LT3297631T (es)
MX (2) MX377052B (es)
PL (1) PL3297631T3 (es)
PT (1) PT3297631T (es)
RS (1) RS59608B1 (es)
RU (1) RU2743206C2 (es)
SI (1) SI3297631T1 (es)
SM (1) SMT201900719T1 (es)
WO (1) WO2016184829A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3384930A1 (en) 2013-03-15 2018-10-10 AbbVie Inc. Compositions for use in treating heavy menstrual bleeding
SG11202008226YA (en) * 2018-03-14 2020-09-29 Kandy Therapeutics Ltd Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists
CN112261942A (zh) * 2018-04-19 2021-01-22 艾伯维公司 治疗重度月经出血的方法
JP7673064B2 (ja) 2019-11-15 2025-05-08 カンディー セラピューティクス リミテッド Ｎｔ－８１４の重要な中間体である６－クロロ－４－（４－フルオロ－２－メチルフェニル）ピリジン－３－アミンを作製するための新規な化学的方法
MX2023001199A (es) * 2020-07-30 2023-03-13 Acer Therapeutics Inc Antagonistas de receptor nk para pacientes con cancer.
CA3188730A1 (en) 2020-08-12 2022-02-17 Christopher Barnes Methods and compositions for treating polycystic ovary syndrome
WO2023147135A1 (en) * 2022-01-31 2023-08-03 Acer Therapeutics, Inc. Nk receptor antagonists for treatment of prostate cancer
EP4431512A1 (en) * 2023-03-16 2024-09-18 Bayer Consumer Care AG Novel dual nk-1/nk-3 receptor antagonists
WO2025242585A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant
WO2025242583A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Novel formulation comprising elinzanetant in a solid dispersion
WO2025242584A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag A stable soft gelatin capsule formulation for elinzanetant
WO2025261856A1 (en) 2024-06-18 2025-12-26 Bayer Consumer Care Ag Improved process for producing an elinzanetant precursor

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69531458T2 (de) * 1994-05-27 2004-08-05 Glaxosmithkline S.P.A. Chinolinderivate als tachykinin nk3 rezeptor antagonisten
MX9700574A (es) * 1994-07-22 1997-12-31 Hampton Roads Medical College Metodo para establecer la secrecion de estrogeno tonico ovarico para regimenes terapeuticos prolongados.
GB9907571D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Compounds
US20020016283A1 (en) * 2000-06-12 2002-02-07 Guttuso Thomas J. Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist
EP1192952A3 (en) 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
WO2002089802A2 (en) * 2001-05-08 2002-11-14 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
US7041682B2 (en) * 2002-07-03 2006-05-09 Schering Corporation NK1 antagonists
JO2696B1 (en) 2002-12-23 2013-03-03 شركة جانسين فارماسوتيكا ان. في Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists
CA2509090C (en) 2002-12-23 2012-01-24 Janssen Pharmaceutica N.V. Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists
US7525659B2 (en) 2003-01-15 2009-04-28 Negevtech Ltd. System for detection of water defects
AU2004253267B2 (en) 2003-07-03 2008-12-04 F. Hoffmann-La Roche Ag Dual NK1/NK3 antagonists for treating schizophrenia
JO2676B1 (en) 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
JO2525B1 (en) 2004-04-08 2010-03-17 شركة جانسين فارماسوتيكا ان. في Derived 4-alkyl-and-4-canoelperidine derivatives and their use as anti-neroquin
BRPI0510951A (pt) 2004-05-12 2007-11-20 Pfizer Prod Inc derivados de piperidina como antagonistas de nk1 e nk3
DE102004033902A1 (de) 2004-07-14 2006-02-16 Zentaris Gmbh Neue Tetrahydrocarbazolderivate mit verbesserter biologischer Wirkung und verbesserter Löslichkeit als Liganden für G-Protein gekoppelte Rezeptoren (GPCR's)
WO2006013205A1 (en) 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation
US20060030600A1 (en) 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
AU2006289281B2 (en) * 2005-09-09 2012-05-17 KaNDy Therapeutics Ltd. Pyridine derivatives and their use in the treatment of psychotic disorders
JP2009510066A (ja) * 2005-09-29 2009-03-12 ワイス 血管運動症状（ｖｍｓ）の治療のためのモノアミン再取り込みのモジュレータである１−（１ｈ−インドール−１−イル）−３−（メチルアミノ）−１−フェニルプロパン−２−オール誘導体および関連の化合物
EP2137213A4 (en) * 2007-03-27 2010-06-09 Christopher M Hovens METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER
EP2148857B1 (en) 2007-04-20 2010-07-28 F. Hoffmann-La Roche AG Pyrrolidine derivatives as dual nk1/nk3 receptors antagonists
GB0814340D0 (en) * 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
EP2470545B1 (en) * 2009-08-27 2013-10-09 NeRRe Therapeutics Limited Anhydrate forms of a pyridine derivative
US8415884B2 (en) 2009-09-08 2013-04-09 Tokyo Electron Limited Stable surface wave plasma source
US8487102B2 (en) 2010-04-20 2013-07-16 Hoffmann-La Roche Inc. Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
CA2800811C (en) * 2010-05-28 2019-02-26 The Board Of Regents Of The University Of Texas System Oligo-benzamide compounds and their use
US9446029B2 (en) 2010-07-27 2016-09-20 Colorado State University Research Foundation Use of NK-1 receptor antagonists in management of visceral pain
ES2376564B1 (es) 2010-08-12 2013-01-24 Manuel Vicente Salinas Martín Utilización de anticuerpos contra los receptores nk1, nk2 y/o nk3, para producir apoptosis en las células tumorales y modificar el estroma, la inmunidad y la vascularización intra y peritumorales, como tratamiento del cáncer.
WO2014089019A1 (en) 2012-12-03 2014-06-12 University Of Washington Through Its Center For Commercialization Methods and compositions for treating vasomotor symptoms
GB201315846D0 (en) 2013-09-05 2013-10-23 Imp Innovations Ltd Method for treating or preventing hot flushes
SG11202008226YA (en) * 2018-03-14 2020-09-29 Kandy Therapeutics Ltd Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists

Also Published As

Publication number Publication date
BR112017024852A2 (pt) 2018-08-07
AU2016264034A1 (en) 2017-10-26
RU2017134908A (ru) 2019-06-18
US20210128574A1 (en) 2021-05-06
DK3297631T3 (da) 2019-11-11
EP3297631B1 (en) 2019-09-04
WO2016184829A1 (en) 2016-11-24
PL3297631T3 (pl) 2020-03-31
JP2018515445A (ja) 2018-06-14
SMT201900719T1 (it) 2020-01-14
HUE047732T2 (hu) 2020-05-28
CN114306335A (zh) 2022-04-12
MX2017012720A (es) 2018-02-09
US20210236506A1 (en) 2021-08-05
RS59608B1 (sr) 2020-01-31
LT3297631T (lt) 2019-10-25
AU2016264034B2 (en) 2020-03-05
AU2020201074B2 (en) 2021-07-29
MX377052B (es) 2025-03-07
CA2984591A1 (en) 2016-11-24
CN114272242A (zh) 2022-04-05
RU2017134908A3 (es) 2019-10-23
EP3297631A1 (en) 2018-03-28
BR112017024852B1 (pt) 2023-10-31
EP3574907A1 (en) 2019-12-04
JP6902682B2 (ja) 2021-07-14
KR20180004815A (ko) 2018-01-12
EP3574907C0 (en) 2023-08-23
US10195205B2 (en) 2019-02-05
CN114306347A (zh) 2022-04-12
US20260014166A1 (en) 2026-01-15
PT3297631T (pt) 2019-10-10
AU2020201074A1 (en) 2020-03-05
CN107635557A (zh) 2018-01-26
US20160339037A1 (en) 2016-11-24
KR102704783B1 (ko) 2024-09-10
ES2753539T3 (es) 2020-04-13
RU2743206C2 (ru) 2021-02-16
SI3297631T1 (sl) 2019-12-31
EP3574907B1 (en) 2023-08-23
CY1122180T1 (el) 2020-11-25
HRP20192132T1 (hr) 2020-02-21

Similar Documents

Publication Publication Date Title
MX2020011668A (es) Antagonistas duales de receptores de neurocinina-1 (nk-1)/neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales.
PH12018500086A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
GB201709456D0 (en) Therapeutic agents
MY192927A (en) Fused bicyclic compounds for the treatment of disease
NZ767823A (en) Processes and intermediates in the preparation of c5ar antagonists
MX2017008456A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
MX2017014192A (es) Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa.
IL281089A (en) LINGO–1 antagonists and uses for the treatment of demyelinating disorders
IL249455A0 (en) Complexes of mineral-amino acids with active substances
IL269853A (en) Proteins for the treatment of epithelial barrier activity disorders
MX2017001103A (es) Derivados de indolizina que son aplicables a enfermedades neurodegenerativas.
TW201713341A (en) Compositions and methods of treating a neurodegenerative disease
GB201603104D0 (en) Therapeutic agents
PH12018500282A1 (en) Cgrp receptor antagonists
SG10201908881PA (en) Fused bicyclic compounds for the treatment of disease
GB201700553D0 (en) Therapeutic agents
HUE039425T2 (hu) 3,4-Diamino-6-klórpirazin-2-karboxamid vegyületek enac által mediált betegségek kezelésére
GB201600376D0 (en) Novel therapeutic agents
SG11201703330YA (en) Iminosugars useful for the treatment of viral diseases
MA54630A (fr) N,n-bis-2-mercaptoéthyle isophtalamide pour le traitment des maladies neurodégénératives
PL3494122T3 (pl) Podstawione rybonukleozydy heteropentadienopirolopirymidynowe do użytku terapeutycznego
GB201620948D0 (en) Therapeutic agents
GB201616563D0 (en) Therapeutic agents
IL246817A0 (en) Strength testing for medical agents
GB201702047D0 (en) Therapeutic agents